Assessing Bio-Rad Laboratories after recent performance Bio-Rad Laboratories (BIO) has attracted attention after a mixed stretch of returns, with the stock roughly flat over the past year but showing ...

Today, we will review the fourth quarter and full year 2025 financial results and provide an update on key business trends ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...

Bio-Rad Laboratories missed estimated earnings by -5.28%, reporting an EPS of $2.51 versus an estimate of $2.65. Revenue was up $25.70 million from the same period last year. In the previous quarter, ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Bio-Rad Laboratories (BIO) ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are wondering whether Bio-Rad Laboratories is starting to look ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...

(RTTNews) - Bio-Rad Laboratories, Inc. (BIO), a life science and diagnostic company, on Thursday, reported strong financial performance for the fourth quarter and full year 2025. The company posted ...

Bio-Rad Laboratories Inc. (BIO) reported its Q4 2025 earnings with an EPS of $2.51, falling short of the forecasted $2.71. The revenue slightly surpassed expectations, coming in at $693.2 million ...

Bio-Rad Laboratories Inc (NYSE:BIO) presented its fourth quarter and full-year 2025 financial results on February 12, 2026, revealing modest overall growth driven primarily by its Clinical Diagnostics ...